ArticleInternational journal of proteomics2011
Proteomics in melanoma biomarker discovery: great potential, many obstacles.
Article in International journal of proteomics, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 39 citations in OpenAlex.
- Spatial Proteomics as a Potential Decision-Support Layer for Early Melanoma: A Narrative Review.International journal of dermatology · 2026Review
- Solvent Interaction Analysis: A New Lens for Protein Structure and Diagnostics.International journal of molecular sciences · 2026Review
- Melanoma treatment in the era of nanotechnology and precision medicine.Journal of nanobiotechnology · 2025Review
- Probing Wnt pathway and functional signal in equine melanocytic neoplasms through quantitative proteomics and immunohistochemistry.BMC veterinary research · 2025Article
- Review
- Precision Medicine and Melanoma: Multi-Omics Approaches to Monitoring the Immunotherapy Response.International journal of molecular sciences · 2021Review
- Decoding Melanoma Development and Progression: Identification of Therapeutic Vulnerabilities.Frontiers in oncology · 2020Review
- Concurrent Targeting of Glutaminolysis and Metabotropic Glutamate Receptor 1 (GRM1) Reduces Glutamate Bioavailability in GRM1Cancer research · 2019Article
- Complementarity of Matrix- and Nanostructure-Assisted Laser Desorption/Ionization Approaches.Nanomaterials (Basel, Switzerland) · 2019Review
- Article
- Vitronectin and dermcidin serum levels predict the metastatic progression of AJCC I-II early-stage melanoma.International journal of cancer · 2016Article
- Proteomics and melanoma: a current perspective.Global dermatology · 2016Article
- Proteomic Findings in Melanoma.Journal of proteomics & bioinformatics · 2016Article
- Biomarkers for Bone Tumors: Discovery from Genomics and Proteomics Studies and Their Challenges.Molecular medicine (Cambridge, Mass.) · 2016Article
- A Well-Controlled Experimental System to Study Interactions of Cytotoxic T Lymphocytes with Tumor Cells.Frontiers in immunology · 2016Article
- Article
- Serum peptidomic biomarkers for pulmonary metastatic melanoma identified by means of a nanopore-based assay.Cancer letters · 2013Article
- Quantitative Proteomics Identifies Activation of Hallmark Pathways of Cancer in Patient Melanoma.Journal of proteomics & bioinformatics · 2013Article
- Protein target quantification decision tree.International journal of proteomics · 2013Article
- Performance reproducibility index for classification.Bioinformatics (Oxford, England) · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The present clinical staging of melanoma stratifies patients into heterogeneous groups, resulting in the application of aggressive therapies to large populations, diluting impact and increasing toxicity. To move to a new era of therapeutic decisions based on highly specific tumor profiling, the discovery and validation of new prognostic and predictive biomarkers in melanoma is critical. Genomic profiling, which is showing promise in other solid tumors, requires fresh tissue from a large number of primary tumors, and thus faces a unique challenge in melanoma. For this and other reasons, proteomics appears to be an ideal choice for the discovery of new melanoma biomarkers. Several approaches to proteomics have been utilized in the search for clinically relevant biomarkers, but to date the results have been relatively limited. This article will review the present work using both tissue and serum proteomics in the search for melanoma biomarkers, highlighting both the relative advantages and disadvantages of each approach. In addition, we review several of the major obstacles that need to be overcome in order to advance the field.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.